Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1‐5 trials

The efficacy and safety of semaglutide vs comparators in non‐elderly (<65 years) and elderly (≥65 years) patients with type 2 diabetes (T2D) across the SUSTAIN 1‐5 trials were evaluated. Patients were randomized to once‐weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exen...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, Mark, Chaykin, Louis, Trachtenbarg, David, Nayak, Gurudutt, Wijayasinghe, Nelun, Cariou, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099273/
https://www.ncbi.nlm.nih.gov/pubmed/29687620
http://dx.doi.org/10.1111/dom.13331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099273/
https://www.ncbi.nlm.nih.gov/pubmed/29687620
http://dx.doi.org/10.1111/dom.13331

Ejemplares similares